SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN), a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function, today issued the following statement regarding Roche’s decision to extend for the second time its unsolicited tender offer to acquire all outstanding shares of Illumina for $44.50 in cash per common share:
"Illumina’s Board of Directors continues to believe that Roche's offer is grossly inadequate, and that Illumina is positioned to create far more value than Roche has offered. Our stockholders clearly agree."
"Illumina’s Board of Directors continues to believe that Roche's offer is grossly inadequate, and that Illumina is positioned to create far more value than Roche has offered. Our stockholders clearly agree."
